N/A N=108 Obstructive Sleep Apnea in Pregnancy
Sleep Apnea, Obstructive · Pregnancy · Obesity, Morbid
Primary: Number of Participants With a Negative Obstructive Sleep Apnea (OSA) Home Sleep Test Result — 61 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=280 Point-of-care Health Literacy and Activation Information to Improve Diabetes Care
Diabetes Mellitus
Primary: Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During Intervention — 9.11; 9.06; 8.61; 9.04 Percentage/DCCT — p=0.003
N/A N=57 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With ABC
Breast Neoplasms · Carcinoma, Ductal · Adenocarcinoma
Primary: Efficacy of Active Breathing Coordinator (ABC) Device as Determined by the Mean Apical Perfusion Score — 1.2; 2.0; 2.1; 2.5 Mean Perfusion Score
N/A N=4 A Novel Treatment for Aphasia and Apraxia of Speech : Measurement of Outcomes
Apraxia of Speech · Aphasia
Primary: Change in Language Content Production for Treated Stimuli: Effect Sizes (Magnitude of Change From Baseline to Follow-up) — 13.38 units on a scale
N/A N=4,488 National Prevalence and Impact of Noninvasive Prenatal Testing
Aneuploidy
Primary: Number of Patient Undergoing IDTFK Before (Control) and After (Test) NIPT Testing Came to Market — 1414; 3074 Participants
Phase 2 N=104 Efficacy and Dose Ranging Study of Seroguard
Adhesion
Primary: Number of Participants With Reduction of Adhesions Number by 3 or More — 1; 1; 10; 10 Participants
Phase 4 N=60 Comparison of Postoperative Delirium in Patients Anaesthetised With Isoflurane and Desflurane During Spinal Surgery
Postoperative Delirium
Primary: Comparison of Postoperative Delirium(POD) With Isoflurane and Desflurane on Adults Undergoing Spine Surgery — 3; 4; 27; 26 Participants
N/A N=168 An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)
Crohn's Disease · Rheumatoid Arthritis · Psoriasis
Primary: Change From Baseline in WHODAS 2.0 Response Score at Month 6 Across All Indications — 7.9 units on a scale — p=< 0.001
Phase 1 N=30 Bioequivalence Study Comparing Mucinex Extended-release 600 mg Tablets to Immediate-release Guaifenesin 600 mg in Healthy Volunteers
Healthy Subjects
Primary: Maximum Observed Plasma Concentration (Cmax) of Guaifenesin — 857; 1390 ng/mL
Phase 2 N=43 A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
Uterine Fibroids
Primary: Percentage of Participants in Amenorrhea at the End of Treatment Course 1 — 58.33; 70.59; 0.0 percentage of participants — p=0.0008
Phase 2 N=352 A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
Huntington's Disease
Primary: Change From Baseline in UHDRS-TMS at Week 52 — 1.3; 1.4; 2.0; 11.0 units on a scale — p=0.4853
N/A N=174 Filtered Sunlight Phototherapy to Treat Significant Jaundice: Safety and Efficacy in Neonates
Jaundice, Neonatal
Primary: Efficacy of Phototherapy — 116; 135 treatment days
Phase 1 N=17 A Study of LY2881835 in Healthy People and People With Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With Clinically Significant Adverse Effects — 0; 0; 1; 0 participants
Phase 2 N=421 Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma
Asthma
Primary: Mean Change From Baseline in Clinic Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 — 0.1289; 0.3046; 0.3130 Liters — p=<0.001
Phase 2 N=51 Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia · Neuropathy · Neuropathic Pain
Primary: Daily Total Dose of Oral Morphine (mg/kg/Day). — 0.38267; 0.27433; 0.43685; 0.31816 mg/kg/day